Saitoh Jun-Ichi, Shirai Katsuyuki, Imaeda Masumi, Musha Atsushi, Abe Takanori, Shino Masato, Takayasu Yukihiro, Takahashi Katsumasa, Chikamatsu Kazuaki, Nakano Takashi
Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Gunma University Heavy Ion Medical Center, Maebashi, Gunma, Japan.
Radiat Oncol. 2017 Feb 20;12(1):39. doi: 10.1186/s13014-016-0741-4.
To assess the efficacy of concurrent chemoradiotherapy (CCRT) with daily low-dose cisplatin (CDDP) plus weekly docetaxel (DTX) for patients with T2N0 glottic cancer.
Between January 2004 and December 2013, 62 treatment-naive patients with histologically proven T2N0 glottic cancer were treated with concurrent chemoradiotherapy. Radiation therapy (RT; 2 Gy daily fractions up to a total dose of 66 Gy) was administered in combination with daily low-dose CDDP (6 mg/m, five times a week), plus weekly DTX (10 mg/m) for up to 4 weeks from the commencement of RT.
Median duration of follow-up was 70 months. The actuarial 3-year and 5-year overall survival rates were 95% and 93%. The 3-year and 5-year cause-specific survival rates were both 100%. The actuarial 3-year and 5-year local control rates were 94% and 94%, respectively. Hematologic toxicity (neutoropenia of severity ≥ Grade 3) was observed in 8% of the patients, and non-hematologic toxicity (radiation mucositis of severity ≥ Grade 3) developed in one patient (2%). Radiation dermatitis of severity ≥ Grade 3 and laryngeal necrosis developed in one patient.
CCRT with weekly DTX and low-dose CDDP appears to be a practical and safe modality and is expected to improve local control.
UMIN000025046 . Registered 1 October 2015, retrospectively registered.
评估每日低剂量顺铂（CDDP）联合每周多西他赛（DTX）同步放化疗（CCRT）治疗T2N0声门癌患者的疗效。
2004年1月至2013年12月期间，62例未经治疗的组织学确诊为T2N0声门癌患者接受同步放化疗。放疗（RT；每日2Gy分次照射，总剂量达66Gy）联合每日低剂量CDDP（6mg/m²，每周5次），并从放疗开始起每周联合DTX（10mg/m²），共4周。
中位随访时间为70个月。3年和5年总生存率分别为95%和93%。3年和5年病因特异性生存率均为100%。3年和5年局部控制率分别为94%和94%。8%的患者出现血液学毒性（≥3级中性粒细胞减少），1例患者（2%）出现非血液学毒性（≥3级放射性黏膜炎）。1例患者出现≥3级放射性皮炎和喉坏死。
每周DTX和低剂量CDDP同步放化疗似乎是一种实用且安全的治疗方式，有望提高局部控制率。
UMIN000025046。2015年10月1日注册，回顾性注册。
